Praxis Precision’s relutrigine reduces seizures in rare epileptic disorders in phase 2 clinical trials
Relutrigine resulted in a 46% reduction in seizures and seizure freedom in 30% of patients. Patients also experienced meaningful improvements...
GSK: Depemokimab Monoclonal Antibody Reduces Asthma Attacks
Depemokimab was shown to reduce exacerbations in patients with severe asthma. The proportions of adverse events of Depemokimab and the...
Incyte and Syndax: Niktimvo led to significant disease response rates in patients with recurrent chronic graft-versus-host-disease (cGVHD).
All three tested Niktimvo dosing regimens led to statistically significant overall response rates in patients who have undergone allogenic hematopoietic...
Tarsus Pharmaceuticals’ Xdemvy demonstrates positive efficacy and safety in treatment for patients with Demodex blepharitis.
Xdemvy is the first and only approved FDA treatment for Demodex blepharitis Xdemvy can achieve collarette reduction of no more...
Levicept: LEVI-04 Reduces Osteoarthritis Pain
Patients with chronic pain from osteoarthritis who received LEVI-04 had a 50% reduction in pain from baseline. LEVI-04 was well...
BioNTech’s mRNA Cancer Candidate Packs A Punch With Regeneron’s Cemiplimab In Phase 2 Melanoma Trial
Treatment with BNT111 + cemiplimab showed a statistically significant overall response in patients with inoperable or advanced-stage anti-PD-1 refractory melanoma...
Eli Lilly: Kisunla was shown to reduce symptoms and slow disease progression in adults with early symptomatic Alzheimer’s disease.
Compared to the placebo, patients treated with Kisunla had a 35% slower cognitive and functional decline at 18 months of...
Pfizer’s First Of Its Kind Gene Therapy Shines In Phase 3 Trials For Treatment of Hemophilia A
Giroctocogene fitelparvovec, a novel gene therapy, demonstrated superiority to routine therapy in treating hemophilia A. Giroctocogene fitelparvovec resulted in a...
uniQure: AMT-130 Gene Therapy Slows Progression of Huntington’s Disease
A dose-dependent slowing in Huntington's disease progression was observed after 24 months in patients receiving high-dose AMT-130. The gene therapy...
GSK’s Jemperli in combination with chemotherapy shows improved overall survival in patients with endometrial cancer.
Jemperli in combination with chemotherapy showed a 31% reduction in the risk of death and a 16.4-month improvement in median...